#USA #New York #BrainStorm #ALS #Cell Therapeutics

BrainStorm Advocates for FDA Regulation Updates

BrainStorm Cell Therapeutics Inc. recently released a compelling article addressing the urgent need to update US FDA regulatory frameworks concerning ALS, rare diseases, and regenerative medicine. This timely publication aligns with Lou Gehrig Day, a date that honors the bravery of individuals battling ALS, and emphasizes the importance of health frameworks in light of medical advancements.

Co-authored by former FDA Associate Commissioner Peter J. Pitts and BrainStorm President and CEO Chaim Lebovits, the article titled 'Restoring Regulatory Fairness and Reclaiming Biomedical Leadership ALS, Rare Disease Regulation, and the Future of Regenerative Medicine' appears in the Journal of the Academy of Public Health. The authors make a strong case for the acceptance and integration of contemporary approaches in drug regulation to keep pace with the breakthrough scientific advancements in biomarkers, artificial intelligence, and cell therapies.

As science continues to progress at a rapid rate, existing regulatory systems often lag behind with outdated models of evidence generation. The authors argue that individuals with serious and aggressively progressing diseases like ALS may be deprived of potential benefits from modern medical science if regulatory tools do not evolve. They propose that regulatory bodies must embrace new methodologies, tools, and frameworks that could facilitate timely access to innovative therapies for patients.

Peter Pitts emphasizes, “We’re asking regulators to evaluate 21st-century science with the most up-to-date tools,” referring to advanced methodologies such as Accelerated Approval, adaptive trial design, and biomarker qualification that could greatly enhance therapy development for ALS.

The publication discusses various strategies, including the use of validated biomarkers, surrogate endpoints, and adaptive trial designs, which can improve the development processes for ALS therapeutics. For conditions where patient populations are small and clinical measurements take extensive timeframes, these updated strategies may be crucial to expedite the therapy availability.

Chaim Lebovits also pointed out that the system must evolve as science progresses: “Our Special Protocol Assessment, the first ever granted in ALS, is a good example of what is possible when a sponsor and regulator work together in good faith.” This highlights how collaborative efforts can lead to innovative solutions for regulatory concerns.

BrainStorm has been at the forefront of developing autologous stem cell therapies aimed at tackling debilitating neurodegenerative diseases. Their lead candidate, NurOwn®, involves the use of patients' own mesenchymal stem cells to produce beneficial substances that may halt or reverse ALS progression. The development and approval of this therapeutic candidate underscore the necessity of evolving regulatory measures. As a key milestone, BrainStorm’s NurOwn® is under a Special Protocol Assessment agreement with the FDA, a noteworthy achievement that signals progress in ALS therapy development.

In conclusion, the publication pushes for a transformative shift in regulatory practices, aligning them with the advancements in medical science, thereby ensuring patients have timely access to innovative treatments. Amid the ongoing struggle against ALS and various rare diseases, the call for updated FDA approaches resonates strongly, driving home the message that in the realm of healthcare, stagnation is not an option.

For more details, visit BrainStorm’s official site.